Endometrial pathologies associated with postmenopausal tamoxifen treatment

Gynecologic Oncology

Volumn 94, Issue 2, 2004, Pages 256-266

  Cohen, Ilan ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Endometrial pathologies; Menopause; Tamoxifen

Indexed keywords

TAMOXIFEN;

BREAST CANCER; DISEASE ASSOCIATION; DOSE RESPONSE; ENDOMETRIAL DISEASE; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ENDOMETRIUM SARCOMA; EVALUATION; HUMAN; MEDLINE; MENOPAUSAL SYNDROME; MESODERM; PATHOLOGY; POLYP; PRIORITY JOURNAL; RANDOMIZATION; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; POLYPS; POSTMENOPAUSE; TAMOXIFEN; UTERINE DISEASES;

EID: 3543100346     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.048     Document Type: Review

References (106)

1. Neven P., De Muylder X., Van Belle Y., et al. Tamoxifen and the uterus and endometrium. Lancet. 2:1989;375
2. Gal D., Kopel S., Bashevkin M. Oncogenic potential of tamoxifen on endometrium of postmenopausal women with breast cancer: a preliminary report. Gynecol. Oncol. 42:1991;120-123
3. De Muylder X., Neven P., De Somer M. Endometrial lesions in patients undergoing tamoxifen therapy. Int. J. Gynecol. Pathol. 36:1991;127-129
4. Cohen I., Rosen D.J.D., Shapira J., et al. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br. J. Obstet. Gynaecol. 100:1993;567-570
5. Lahti E., Blanco G., Kauppila A., et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet. Gynecol. 81:1993;660-664
6. Uziely B., Lewin A., Braufman G., et al. The effect of tamoxifen on the endometrium. Breast Cancer Res. Treat. 26:1993;101-105
7. Cohen I., Rosen D.J.D., Shapira J., et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and non-treated asymptomatic breast cancer patients. Gynecol. Oncol. 52:1994;185-190
8. Cohen I., Tepper R., Rosen D.J.D., et al. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies. Gynecol. Oncol. 55:1994;138-143
9. Ismail S.M. Pathology of endometrium treated with tamoxifen. J. Clin. Pathol. 47:1994;827-833
10. Kedar R.P., Bourne T.H., Powels T.J., et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet. 343:1994;1318-1321
11. Borenstein J., Ausllender R., Pascal B., et al. Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. J. Reprod. Med. 39:1994;674-678
12. Cohen I., Altaras M.M., Shapira J., et al. Time-dependent effect of tamoxifen therapy on endometrial pathologies in asymptomatic, postmenopausal breast cancer patients. Int. J. Gynecol. Pathol. 15:1996;152-157
13. Gibson L.E., Bararkat R.R., Venkatraman E.S. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and non-users. Cancer J. 2:1996;35-38
14. Hann L.E., Geiss C.S., Bach A.M., et al. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. AJR. 168:1997;657-661
15. Cohen I., Altaras M.M., Shapira J., Beyth Y. Different coexisting endometrial histological features in asymptomatic postmenopausal breast cancer patients treated with tamoxifen. Gynecol. Obstet. Invest. 43:1997;60-63
16. Cheng W.-F., Lin H.-H., Torng P.-L., et al. Comparison of endometrial changes among symptomatic tamoxifen treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol. Oncol. 66:1997;233-237
17. Nouvo M.A., Nouvo G.J., McCaffrey R.M., et al. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int. J. Gynecol. Pathol. 8:1989;125-131
18. Corley D., Rowe J., Curtis M., et al. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet. Gynecol. 79:1992;111-116
19. Cohen I., Perel E., Tepper R., et al. Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients. Breast Cancer Res. Treat. 53:1999;255-262
20. Cohen I., Perel E., Flex D., et al. Endometrial pathologies in postmenopausal tamoxifen treatment: comparison between gynaecological symptomatic and gynaecological asymptomatic breast cancer patients. J. Clin. Pathol. 52:1999;278-282
21. Gerber B., Krause A., Muller H., et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J. Clin. Oncol. 18:2000;3464-3470
22. Marconi D., Exacoustos C., Cangi B., et al. Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen. J. Am. Gynecol. Laparosc. 4:1997;331-339
23. Exacoustos C., Zupi E., Cangi B., et al. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound colour flow Doppler, hysteroscopic and histologic study. Ultrasound Obstet. Gynecol. 6:1995;435-442
24. Timmerman D., Deprest J., Bourne T., et al. A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. Am. J. Obstet. Gynecol. 179:1998;62-70
25. Bertelli G., Venturini M., Del Mastro L., et al. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res. Treat. 47:1998;41-46
26. Love C.D.B., Muir B.B., Scrimgeour J.B., et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J. Clin. Oncol. 17:1999;2050-2054
27. Mourits M.J.E., Van der Zee A.G.J., Willemse P.H.B., et al. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol. Oncol. 73:1999;21-26
28. Tesoro M.R., Borgida A.F., MacLaurin N.A., et al. Transvaginal endometrial sonography in postmenopausal women taking tamoxifen. Obstet. Gynecol. 93:1999;363-366
29. Seoud M.A.-F., Shamseddine A., Kahlil A., et al. Tamoxifen and endometrial pathologies: a prospective study. Gynecol. Oncol. 75:1999;15-19
30. Cohen I., Azaria R., Bernheim J., et al. Comparison of endometrial pathologies collected by hysteroscopy and hysterectomy in postmenopausal breast cancer tamoxifen-treated patients. Eur. J. Gynaecol. Oncol. 21:2000;418-422
31. Cohen I., Azaria R., Shapira J., et al. The significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women. Cancer. 94:2000;3101-3106
32. Zarbo G., Caruso G., Zammitti M., et al. The effect of tamoxifen therapy on the endometrium. Eur. J. Gynaecol. Oncol. 21:2000;86-88
33. Willen R., Lindhal B., Andolf E., et al. Histopathologic findings in thickened endometria, as measured by ultrasound in asymptomatic, postmenopausal breast cancer patients on various adjuvant treatment including tamoxifen. Anticancer Res. 18:1998;667-676
34. Berliere M., Charles A., Galant C., et al. Uterine side effects of tamoxifen: a need for systemic pretreatment screening. Obstet. Gynecol. 191:1998;40-44
35. Goncalves M.A.G., Goncalves W.J., Matias M.M., et al. Hysteroscopic evaluation of the endometrium of postmenopausal patients with breast cancer before and after tamoxifen use. Int. J. Gynecol. Obstet. 66:1999;273-279
36. Neven P., De Mylder X., Van Belle Y., et al. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet. 351:1998;36
37. Maugeri G., Nardo L.G., Campione C., et al. Endometrial lesions after tamoxifen therapy in breast cancer women. Breast J. 7:2001;240-244
38. Wolf D.M., Jordan V.C. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol. Oncol. 45:1992;118-128
39. Fornander T., Cedermak B., Mattson A., et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. I:1989;117-120
40. Mignotte H., Lasset C., Bonadona V., et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int. J. Cancer. 76:1998;325-330
41. Jordan V.C., Assikis V.J. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin. Cancer Res. 1:1995;467-472
42. Andersson M., Storm H., Mouridsen T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J. Natl. Cancer Inst. 83:1991;1013-1017
43. Fisher B., Costantino J.P., Redmond C.K., et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86:1994;527-537
44. van Leeuwen F.E., Benraadt J., Coebergh J.W.W., et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 343:1994;448-452
45. Deligdisch L., Kalir N., Cohen C.J., et al. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol. Oncol. 78:2000;181-186
46. McGonigle K.F., Lanntry S.A., Odom-Maryon T.L., et al. Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status. Cancer Lett. 101:1996;59-66
47. Tepper R., Beyth Y., Altaras M.M., et al. Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol. Oncol. 64:1997;386-391
48. Ozsener S., Ozsaran A., Itil I., et al. Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen. Eur. J. Gynaecol. Oncol. 19:1998;580-583
49. McGonigle K.F., Shaw S.L., Vasilev S.A., et al. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am. J. Obstet. Gynecol. 178:1998;1145-1150
50. Schlesinger C., Kamoi S., Ascher S., et al. Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups. Int. J. Gynecol. Pathol. 17:1998;302-311
51. Barakat R.R., Gilewski T.A., Almadrones L., et al. Effect of tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J. Clin. Oncol. 8:2000;3459-3463
52. Narod S.A., Pal T., Graham T., et al. Tamoxifen and risk of endometrial cancer. Lancet. 357:2001;65-66
53. Ramondetta L.M., Sherwood J.B., Dunton J.D., et al. Endometrial cancer in polyps associated with tamoxifen use. Am. J. Obstet. Gynecol. 180:1999;340-341
54. Cohen I., Bernheim J., Azaria R., et al. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol. Oncol. 75:1999;136-141
55. Liedman R., Lindhal B., Andolf B., et al. Discordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res. 20:2000;4889-4892
56. Cohen I., Azaria R., Bernheim J., et al. Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen. Cancer. 92:2001;1151-1155
57. Assikis V.J., Neven P., Jordan V.C., et al. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur. J. Cancer. 32A:1996;1464-1476
58. Fotiou S., Hatjeleftheriou G., Kyrousis G., et al. Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature. Anticancer Res. 20:2000;2015-2020
59. Clement P.B., Oliva E., Young R.H. Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen associated endometrial lesions. Int. J. Gynecol. Pathol. 15:1996;222-229
60. Ribero G., Swindell R. The Christie Hospital adjuvant tamoxifen trial - Status at 10 years. Br. J. Cancer. 50:1998;601-603
61. Castiglione M., Gelber R.D., Goldhirsch A. International Breast Cancer Study Group Adjuvant systemic therapy for breast cancer in the elderly: comparing causes of mortality. J. Clin. Oncol. 8:1990;519-526
62. Fornander T., Rutquist L.E., Cedermark B. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J. Clin. Oncol. 9:1991;1740-1748
63. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic and immune therapy. Lancet(1992) 339 1-15, 71-85.
64. Ryden S., Fermo M., Moller T. Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol. 31:1992;271-274
65. Andersson M., Storm H.H., Mouridsen H.T. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol. 31:1992;259-263
66. Boccardo F., Rubagotti A., Amoroso D. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) trial. Eur. J. Cancer. 28:1992;673-680
67. Stewart H.J. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Cancer Group. Monogr. Natl. Cancer Inst. 11:1992;117-120
68. Cummings F.J., Gray R., Tormey D.C., et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J. Clin. Oncol. 11:1993;29-35
69. Magriples U., Naftolin F., Schwartz P.E., et al. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol. 11:1993;485-490
70. Fornander T., Hellstrom A.-C., Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J. Natl. Cancer Inst. 85:1993;1850-1855
71. Seoud M.A.-F., Johnson J., Weed J.C. Gynecologic tumors in tamoxifen-treated women with breast cancer. Gynecol. Oncol. 82:1993;165-169
72. Barakat R.R., Wong G., Curtin J.P., et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol. Oncol. 55:1994;164-168
73. Silva E.G., Carmen S.T., Follen-Mitchell M. Malignant neoplasms of the corpus in patients treated for breast carcinoma: the effect of tamoxifen. Int. J. Gynecol. Pathol. 13:1994;248-258
74. Rutquist L.E., Johnson H., Signomaklo T., et al. Adjuvant tamoxifen therapy for early breast cancer and second primary cancer. J. Natl. Cancer Inst. 87:1995;645-651
75. Cook L.S., Weiss N.S., Shwartz S.M. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancers. J. Natl. Cancer Inst. 87:1995;1359-1364
76. Robinson D.C., Bloss J.D., Schiano M.A. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol. Oncol. 59:1995;186-190
77. Curtis R.E., Boice J.D., Shriner D.A., et al. Second cancers after adjuvant tamoxifen therapy for breast cancer. J. Natl. Cancer Inst. 88:1996;832-834
78. Sasco A.J., Chaplin G., Amoros E., et al. Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiology. 7:1996;9-13
79. Cuenca R.E., Giachino J., Arredondo M.A., et al. Endometrial carcinoma associated with breast carcinoma. Cancer. 77:1996;2058-2063
80. Ragaz J., Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J. Clin. Oncol. 16:1998;2018-2024
81. Katase K., Sugiyama Y., Hasumi K., et al. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Cancer. 82:1998;1698-1703
82. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 351:1998;15451-15467
83. Cohen I., Azaria R., Fishman A., et al. Endometrial cancer in postmenopausal breast cancer patients with tamoxifen treatment. Int. J. Gynecol. Pathol. 18:1999;304-309
84. Bernstein L., Deapen D., Cerhan J.R., et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J. Natl. Cancer Inst. 91:1999;1654-1662
85. Peters-Ingl C., Frank W., Danmayer E., et al. Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res. Treat. 54:1999;255-260
86. Bergman L., Beelen M.L.R., Gallee M.P.W., et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet. 356:2000;881-887
87. Lasset C., Bellen M.L.R., Gallee M.P.W., et al. Tamoxifen and risk of endometrial cancer. Lancet. 357:2001;66
88. Fisher B., Costantino J.P., Wickerham L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1998;1371-1388
89. Stewart H.J., Knight G.M. Tamoxifen and the uterus and endometrium. Lancet (letter). I:1989;375-376
90. Evans M.J., Langlois N.E.J., Kitchener H.C., et al. Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed mesodermal tumor) of the uterus? Int. J. Gynecol. Cancer. 5:1995;310-313
91. McCluggage W.G., McManus D.T., Lioe T.F., et al. Uterine carcinosarcoma in association with tamoxifen therapy. Br. J. Obstet. Gynaecol. 104:1997;748-750
92. McCluggage W.G., Abdulkader M., Price J.H., et al. Uterine carcinosarcoma in patients receiving tamoxifen: a report of 19 cases. Int. J. Gynecol. Cancer. 10:2000;280-284
93. Sasco A.J., Raffi F., Satge J., et al. Endometrial mullerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer. Int. J. Gynecol. Obstet. 48:1995;307-310
94. ACOG Committee Opinion on tamoxifen and endometrial cancer. 2000) 232 104-106.
95. Cecchini S., Ciatto S., Bonardi R., Mazzotta A., et al. Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol. Oncol. 60:1996;409-411
96. Biron-Shental T., Tepper R., Fishman A., Shapira J., Cohen I. Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol. Oncol. 90:2003;382-386
97. Adami H.-O., Krusemo U.B., Bergkvist L., et al. On the age-dependent association between cancer of the breast and of the endometrium. A nationwide cohort study. Br. J. Cancer. 55:1987;77-80
98. Ewertz M., Storm H.H. Multiple primary cancers of the breast, endometrium and ovary. Eur. J. Cancer Clin. Oncol. 25:1989;1927-1932
99. Bouchardy C., Verkooijen H.M., Fioretta Increased risk of malignant mullerian tumors of the uterus among women with breast cancer treated by tamoxifen. J. Clin. Oncol. 20:2002;4403
100. Wickerham D.L., Fisher B., Wolmark N., Bryant, Costantino J., Bernstein L., et al. Association of tamoxifen and uterine sarcoma. J. Clin. Oncol. 20:2002;2758-2760
101. Taylor S.W., Lee-Wilkins K.L., Sparling Y., Goldstein P.J. Evaluation of the tamoxifen-exposed endometrium by transvaginal sonography. Clin. J. Women's Health. 1:2000;10-15
102. Menzin A.W., Gal D. Should women receiving tamoxifen be screened for endometrial cancer? An argument for screening. Cancer Investig. 18:2000;793-795
103. Kalbhen C.L. Imaging of tamoxifen-induced uterine abnormalities. Radiology (Letter). 217:2000;917-918
104. Ascher S.M., Imaoka I., Lage J.M. Tamoxifen-induced uterine abnormalities: the role of imaging. Radiology. 214:2000;29-38
105. Fong K., Kung R., Lytwn A., et al. Endometrial evaluation with transvaginal us and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen. Radiology. 220:2001;765-773
106. Sue-Bergman E.J., Goodman A. Surveillance for endometrial cancer in women receiving tamoxifen. Ann. Intern. Med. 11:1999;127-135